Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
Public ClinicalTrials.gov record NCT03632135. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).
Study identification
- NCT ID
- NCT03632135
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2018 (Actual)
- Primary completion
- Jun 16, 2022 (Actual)
- Completion
- Dec 31, 2023 (Actual)
- Last update posted
- Apr 15, 2025
2018 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente | Los Angeles | California | 90027 | — |
| Keck School of Medicine of the University of Southern California | Los Angeles | California | 90033 | — |
| Louisiana State University Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| Maine Medical Center Research Institute | Scarborough | Maine | 04074 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| Toledo University | Toledo | Ohio | 43614 | — |
| Providence Cancer Center Oncology | Portland | Oregon | 97225 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| The Penn State Univeristy College of Medicine | Hershey | Pennsylvania | 17033 | — |
| Thomas Jefferson University Hospitals | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15212 | — |
| Charleston Area Medical Center | Charleston | West Virginia | 25326 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03632135, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03632135 live on ClinicalTrials.gov.